Uniqure from now on aloneItalian pharma company Chiesi Farmaceutici withdraws from a co-development agreement with gene therapy pioneer Uniqure. This will add US$1.5m to Uniqures expenses this year. more ➔
Neovacs raises €6m through private place...French immunotherapy specialist Neovacs raises 6€m from three US institutional investors. The private placement involves the issuance of more than 9 million shares. more ➔
J&J intensifies vaccine endeavour wit... Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV. more ➔
GSK cancels 30 preclinical and clinical pr... UKs biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious … more ➔
Lesaffre invests €15.5m in phage start-u...French yeast manufacturer Lesaffre acquires an equity stake in US biotech company Intralytix. Paying more than €15m, Lesaffre gains valuable insights into the development and commercialisation of bacteriophage-based … more ➔
€7.6m by CARB-X dangling for AntabioFrench Antabio receives funding by the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Including future milestone payments, Antabio is eligible for up to €7.6m for their … more ➔
Borreliosis vaccine receives FDA Fast Trac...French vaccines expert Valneva SE announced that the FDA has granted Fast Track designation for its Lyme borreliosis vaccine candidate VLA15. more ➔
Roche exits epigenetic drug dealAfter 3 years of collaboration Roche has ended a cancer deal with the Spanish biotech company Oryzon granting the rights to their cancer candidate ORY-1001. more ➔
Ablynx adds Sanofi to its list of pharma p... Belgian nanobody-developer Ablynx NV now also works together with French pharma company Sanofi. The deal is potentially worth €2.4bn but comes with an upfront payment of just €23m. The partners … more ➔
Shire licensed bispecific antibody from No...Swiss biopharmaceutical company Novimmune grants pharma company Shire a worldwide license to develop and commercialise a pre-clinical bispecific antibody candidate for haemophilia A. more ➔
